Project Grant R37CA309045
- The National Cancer Institute awarded the University of Virginia $669,910 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize pharmacist-led tobacco treatment for individuals who smoke and are not ready to make a quit attempt in federally qualified health centers. The project, titled "Optimizing Pharmacist-Led Tobacco Treatment for Individuals Who Smoke and Are Not Ready to Make a Quit Attempt in Federally Qualified Health Centers,"...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $758,490 on August 13, 2026, to conduct a full-scale randomized controlled trial of QuitQuest, a smartphone application designed to help adolescents stop using electronic nicotine delivery systems (ENDS). The award falls under the Cancer Cause and Prevention Research program (CFDA 93.393). QuitQuest is an acceptance and commitment therapy-based mobile application targeting adolescents aged 13–17 who use ENDS. The trial will...
- Grant Award Summary Duke University received a $906,306 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 11, 2025, with completion targeted for August 31, 2028. The award funds development and testing of a telehealth-delivered, cue-based treatment intervention designed to promote smoking cessation among people who smoke lightly (PSLI), defined as those smoking 10 cigarettes per day or fewer. Building...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $586,018 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-arm clinical trial testing augmented doses of nicotine replacement therapy for individuals who use both combustible cigarettes and e-cigarettes and wish to quit both products. The trial will randomize dual-use participants to receive behavioral support combined with...
- The National Cancer Institute of the National Institutes of Health awarded the University of Southern California $426,828 on July 6, 2026, through the Cancer Cause and Prevention Research program (CFDA 93.393) to test regulatory strategies promoting e-cigarette cessation among young adults. The University of Southern California will conduct a study using a simulated vape shop experimental laboratory space ("The Puff Point") to evaluate two innovative policy interventions designed to...
- The National Cancer Institute awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $948,630 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2026, for a naturalistic cohort study examining the real-world effectiveness of smoking cessation aids in US adults. The project will conduct a longitudinal survey study using the Understanding America Study, a nationally representative panel of 20,000 US...
- The National Cancer Institute, within the Department of Health and Human Services, awarded the University of Oklahoma Health Sciences Center $606,142 on August 1, 2026, to conduct a fully powered randomized controlled trial testing a novel mobile messaging intervention designed to increase smoking quit attempts and cessation among adults who initially report not being ready to quit smoking within thirty days. The intervention, called PHOENIX, delivers daily text messages tailored to...
- The National Cancer Institute, an operating division of the Department of Health and Human Services, awarded Chapman University $649,603 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the TRAQ-TO-QUIT smoking cessation intervention study. The research combines three evidence-based approaches into a multilevel intervention: pediatrician-initiated brief advice and referral to cessation services; novel behavioral tele-counseling to guide smokers...
- This Project Grant award of $899,273.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The purpose of the award is to support a research project titled "Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients." The research will be conducted by Washington University in St. Louis, with a sub-award to the Vandeventer Place Research Foundation. The project aims to explore...
The National Cancer Institute awarded Washington State University $560,858 on July 21, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating a remote telehealth intervention combining varenicline and app-based contingency management for rural smokers with alcohol use disorder. The trial will enroll 192 rural smokers seeking smoking cessation treatment and living with an alcohol use disorder. Participants will be randomized to receive varenicline plus app-based contingency management (CM) designed to reduce both alcohol use and smoking. The CM intervention connects a mobile application to low-cost breathalyzer devices, enabling remote monitoring and feedback. The study will use ecological momentary assessment embedded in the CM app to examine how fluctuations in addiction neuroclinical assessment domains interact with daily drinking and smoking patterns. Medication adherence will be monitored using Pillsy, and smoking status will be verified through collection of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) biomarkers. The work addresses a gap in rural substance use treatment access by delivering a completely remote intervention without requiring travel or in-person clinical visits. Performance of work occurs in Spokane, Washington. The award is a project grant with an obligated amount of $560,858 and a period of performance extending through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $560.9k | 7/21/26 |